Abrogating G₂/M checkpoint through WEE1 inhibition in combination with chemotherapy as a promising therapeutic approach for mesothelioma

References

• Bridda A, Padoan I, Mencarelli R, Frego M. Peritoneal mesothelioma: a review. MedGenMed 2007; 9:32; PMID: 17955087
   PubMedGoogle Scholar
• Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet 2005; 366:397 - 408; http://dx.doi.org/10.1016/S0140-6736(05)67025-0; PMID: 16054941
   PubMed Web of Science ®Google Scholar
• Tsao AS, Wistuba I, Roth JA, Kindler HL. Malignant pleural mesothelioma. J Clin Oncol 2009; 27:2081 - 90; http://dx.doi.org/10.1200/JCO.2008.19.8523; PMID: 19255316
   PubMed Web of Science ®Google Scholar
• Zhou BB, Bartek J. Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat Rev Cancer 2004; 4:216 - 25; http://dx.doi.org/10.1038/nrc1296; PMID: 14993903
   PubMed Web of Science ®Google Scholar
• Kawabe T. G2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther 2004; 3:513 - 9; PMID: 15078995
   PubMed Web of Science ®Google Scholar
• Levesque AA, Eastman A. p53-based cancer therapies: Is defective p53 the Achilles heel of the tumor?. Carcinogenesis 2007; 28:13 - 20; http://dx.doi.org/10.1093/carcin/bgl214; PMID: 17088261
   PubMed Web of Science ®Google Scholar
• Lee AY, Raz DJ, He B, Jablons DM. Update on the molecular biology of malignant mesothelioma. Cancer 2007; 109:1454 - 61; http://dx.doi.org/10.1002/cncr.22552; PMID: 17348013
   PubMed Web of Science ®Google Scholar
• Prins JB, Williamson KA, Kamp MM, Van Hezik EJ, Van der Kwast TH, Hagemeijer A, Versnel MA. The gene for the cyclin-dependent-kinase-4 inhibitor, CDKN2A, is preferentially deleted in malignant mesothelioma. Int J Cancer 1998; 75:649 - 53; http://dx.doi.org/10.1002/(SICI)1097-0215(19980209)75:4<649::AID-IJC25>3.0.CO;2-2; PMID: 9466670
   PubMed Web of Science ®Google Scholar
• Sharpless NE, DePinho RA. The INK4A/ARF locus and its two gene products. Curr Opin Genet Dev 1999; 9:22 - 30; http://dx.doi.org/10.1016/S0959-437X(99)80004-5; PMID: 10072356
   PubMed Web of Science ®Google Scholar
• Wong L, Zhou J, Anderson D, Kratzke RA. Inactivation of p16INK4a expression in malignant mesothelioma by methylation. Lung Cancer 2002; 38:131 - 6; http://dx.doi.org/10.1016/S0169-5002(02)00178-2; PMID: 12399123
   PubMed Web of Science ®Google Scholar
• Gazdar AF, Butel JS, Carbone M. SV40 and human tumours: myth, association or causality?. Nat Rev Cancer 2002; 2:957 - 64; http://dx.doi.org/10.1038/nrc947; PMID: 12459734
   PubMed Web of Science ®Google Scholar
• Testa JR, Giordano A. SV40 and cell cycle perturbations in malignant mesothelioma. Semin Cancer Biol 2001; 11:31 - 8; http://dx.doi.org/10.1006/scbi.2000.0344; PMID: 11243897
   PubMed Web of Science ®Google Scholar
• Wang Y, Li J, Booher RN, Kraker A, Lawrence T, Leopold WR, Sun Y. Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator. Cancer Res 2001; 61:8211 - 7; PMID: 11719452
   PubMed Web of Science ®Google Scholar
• Wang Y, Decker SJ, Sebolt-Leopold J. Knockdown of Chk1, Wee1 and Myt1 by RNA interference abrogates G2 checkpoint and induces apoptosis. Cancer Biol Ther 2004; 3:305 - 13; http://dx.doi.org/10.4161/cbt.3.3.697; PMID: 14726685
   PubMed Web of Science ®Google Scholar
• Hirai H, Iwasawa Y, Okada M, Arai T, Nishibata T, Kobayashi M, Kimura T, Kaneko N, Ohtani J, Yamanaka K, et al. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther 2009; 8:2992 - 3000; http://dx.doi.org/10.1158/1535-7163.MCT-09-0463; PMID: 19887545
   PubMed Web of Science ®Google Scholar
• Hirai H, Arai T, Okada M, Nishibata T, Kobayashi M, Sakai N, Imagaki K, Ohtani J, Sakai T, Yoshizumi T, et al. MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil. Cancer Biol Ther 2010; 9:514 - 22; http://dx.doi.org/10.4161/cbt.9.7.11115; PMID: 20107315
   PubMed Web of Science ®Google Scholar
• Indovina P, Giordano A. Targeting the checkpoint kinase WEE1: selective sensitization of cancer cells to DNA-damaging drugs. Cancer Biol Ther 2010; 9:523 - 5; http://dx.doi.org/10.4161/cbt.9.7.11276; PMID: 20150761
   PubMed Web of Science ®Google Scholar
• Bridges KA, Hirai H, Buser CA, Brooks C, Liu H, Buchholz TA, Molkentine JM, Mason KA, Meyn RE. MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells. Clin Cancer Res 2011; 17:5638 - 48; http://dx.doi.org/10.1158/1078-0432.CCR-11-0650; PMID: 21799033
   PubMed Web of Science ®Google Scholar
• Rajeshkumar NV, De Oliveira E, Ottenhof N, Watters J, Brooks D, Demuth T, Shumway SD, Mizuarai S, Hirai H, Maitra A, et al. MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clin Cancer Res 2011; 17:2799 - 806; http://dx.doi.org/10.1158/1078-0432.CCR-10-2580; PMID: 21389100
   PubMed Web of Science ®Google Scholar
• Sarcar B, Kahali S, Prabhu AH, Shumway SD, Xu Y, Demuth T, Chinnaiyan P. Targeting radiation-induced G(2) checkpoint activation with the Wee-1 inhibitor MK-1775 in glioblastoma cell lines. Mol Cancer Ther 2011; 10:2405 - 14; http://dx.doi.org/10.1158/1535-7163.MCT-11-0469; PMID: 21992793
   PubMed Web of Science ®Google Scholar
• PosthumaDeBoer J, Würdinger T, Graat HC, van Beusechem VW, Helder MN, van Royen BJ, Kaspers GJ. WEE1 inhibition sensitizes osteosarcoma to radiotherapy. BMC Cancer 2011; 11:156; http://dx.doi.org/10.1186/1471-2407-11-156; PMID: 21529352
   PubMed Web of Science ®Google Scholar
• Mir SE, De Witt Hamer PC, Krawczyk PM, Balaj L, Claes A, Niers JM, Van Tilborg AA, Zwinderman AH, Geerts D, Kaspers GJ, et al. In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma. Cancer Cell 2010; 18:244 - 57; http://dx.doi.org/10.1016/j.ccr.2010.08.011; PMID: 20832752
   PubMed Web of Science ®Google Scholar
• Cozzi M, Giorgi F, Marcelli E, Pentimalli F, Forte IM, Schenone S, D’Urso V, De Falco G, Botta M, Giordano A, et al. Antitumor activity of new pyrazolo[3,4-d]pyrimidine SRC kinase inhibitors in Burkitt lymphoma cell lines and its enhancement by WEE1 inhibition. Cell Cycle 2012; 11:1029 - 39; http://dx.doi.org/10.4161/cc.11.5.19519; PMID: 22333592
   PubMed Web of Science ®Google Scholar
• O’Connell MJ, Raleigh JM, Verkade HM, Nurse P. Chk1 is a wee1 kinase in the G2 DNA damage checkpoint inhibiting cdc2 by Y15 phosphorylation. EMBO J 1997; 16:545 - 54; http://dx.doi.org/10.1093/emboj/16.3.545; PMID: 9034337
   PubMed Web of Science ®Google Scholar
• Leijen S, Schellens JH, Shapiro G, Pavlick R, Tibes T, Demuth J, Viscusi J, Cheng JD, Xu Y, Oza AM. A phase I pharmacological and pharmacodynamics study of MK-1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors. J Clin Oncol 2010; 28:15s
   PubMed Web of Science ®Google Scholar
• Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22:27 - 55; http://dx.doi.org/10.1016/0065-2571(84)90007-4; PMID: 6382953
   PubMedGoogle Scholar
• Manfredi JJ, Dong J, Liu WJ, Resnick-Silverman L, Qiao R, Chahinian P, Saric M, Gibbs AR, Phillips JI, Murray J, et al. Evidence against a role for SV40 in human mesothelioma. Cancer Res 2005; 65:2602 - 9; http://dx.doi.org/10.1158/0008-5472.CAN-04-2461; PMID: 15805256
   PubMed Web of Science ®Google Scholar
• Pietruska JR, Kane AB. SV40 oncoproteins enhance asbestos-induced DNA double-strand breaks and abrogate senescence in murine mesothelial cells. Cancer Res 2007; 67:3637 - 45; http://dx.doi.org/10.1158/0008-5472.CAN-05-3727; PMID: 17440075
   PubMed Web of Science ®Google Scholar
• Di Marzo D, Forte IM, Indovina P, Di Gennaro E, Rizzo V, Giorgi F, Mattioli E, Iannuzzi CA, Budillon A, Giordano A, et al. Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma. Cell Cycle 2014; 13:652 - 65; http://dx.doi.org/10.4161/cc.27546; PMID: 24345738
   PubMed Web of Science ®Google Scholar
• Brooks CL, Gu W. p53 ubiquitination: Mdm2 and beyond. Mol Cell 2006; 21:307 - 15; http://dx.doi.org/10.1016/j.molcel.2006.01.020; PMID: 16455486
   PubMed Web of Science ®Google Scholar
• Villanova F, Procopio A, Rippo MR. Malignant mesothelioma resistance to apoptosis: recent discoveries and their implication for effective therapeutic strategies. Curr Med Chem 2008; 15:631 - 41; http://dx.doi.org/10.2174/092986708783885273; PMID: 18336278
   PubMed Web of Science ®Google Scholar
• Nilsonne G, Sun X, Nyström C, Rundlöf AK, Potamitou Fernandes A, Björnstedt M, Dobra K. Selenite induces apoptosis in sarcomatoid malignant mesothelioma cells through oxidative stress. Free Radic Biol Med 2006; 41:874 - 85; http://dx.doi.org/10.1016/j.freeradbiomed.2006.04.031; PMID: 16934670
   PubMed Web of Science ®Google Scholar
• Aung W, Hasegawa S, Furukawa T, Saga T. Potential role of ferritin heavy chain in oxidative stress and apoptosis in human mesothelial and mesothelioma cells: implications for asbestos-induced oncogenesis. Carcinogenesis 2007; 28:2047 - 52; http://dx.doi.org/10.1093/carcin/bgm090; PMID: 17434931
   PubMed Web of Science ®Google Scholar
• Hashimoto O, Shinkawa M, Torimura T, Nakamura T, Selvendiran K, Sakamoto M, Koga H, Ueno T, Sata M. Cell cycle regulation by the Wee1 inhibitor PD0166285, pyrido [2,3-d] pyimidine, in the B16 mouse melanoma cell line. BMC Cancer 2006; 6:292; http://dx.doi.org/10.1186/1471-2407-6-292; PMID: 17177986
   PubMed Web of Science ®Google Scholar
• Murrow LM, Garimella SV, Jones TL, Caplen NJ, Lipkowitz S. Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome. Breast Cancer Res Treat 2010; 122:347 - 57; http://dx.doi.org/10.1007/s10549-009-0571-2; PMID: 19821025
   PubMed Web of Science ®Google Scholar
• Kreahling JM, Gemmer JY, Reed D, Letson D, Bui M, Altiok S. MK1775, a selective Wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells. Mol Cancer Ther 2012; 11:174 - 82; http://dx.doi.org/10.1158/1535-7163.MCT-11-0529; PMID: 22084170
   PubMed Web of Science ®Google Scholar
• Domínguez-Kelly R, Martín Y, Koundrioukoff S, Tanenbaum ME, Smits VA, Medema RH, Debatisse M, Freire R. Wee1 controls genomic stability during replication by regulating the Mus81-Eme1 endonuclease. J Cell Biol 2011; 194:567 - 79; http://dx.doi.org/10.1083/jcb.201101047; PMID: 21859861
   PubMed Web of Science ®Google Scholar
• Romagnoli S, Fasoli E, Vaira V, Falleni M, Pellegrini C, Catania A, Roncalli M, Marchetti A, Santambrogio L, Coggi G, et al. Identification of potential therapeutic targets in malignant mesothelioma using cell-cycle gene expression analysis. Am J Pathol 2009; 174:762 - 70; http://dx.doi.org/10.2353/ajpath.2009.080721; PMID: 19218339
   PubMed Web of Science ®Google Scholar
• Pianigiani E, Ierardi F, Mazzanti B, Saccardi R, Cuciti C, Fimiani M. Human de-epidermized dermis as a stem cell carrier. Transplant Proc 2010; 42:2244 - 6; http://dx.doi.org/10.1016/j.transproceed.2010.05.040; PMID: 20692454
   PubMed Web of Science ®Google Scholar
• Indovina P, Giorgi F, Rizzo V, Khadang B, Schenone S, Di Marzo D, Forte IM, Tomei V, Mattioli E, D’Urso V, et al. New pyrazolo[3,4-d]pyrimidine SRC inhibitors induce apoptosis in mesothelioma cell lines through p27 nuclear stabilization. Oncogene 2012; 31:929 - 38; http://dx.doi.org/10.1038/onc.2011.286; PMID: 21785466
   PubMed Web of Science ®Google Scholar